Identification

Name
Artemether
Accession Number
DB06697
Type
Small Molecule
Groups
Approved
Description

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

Structure
Thumb
Synonyms
  • (1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
  • 10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
  • Artemetero
  • Artemetherum
  • Artemisininelactol methyl ether
  • beta-Artemether
  • beta-Dihydroartemisinin methyl ether
  • Dihydroartemisinin methyl ether
  • Dihydroqinghaosu methyl ether
  • Methyl-dihydroartemisinine
  • SM-224
External IDs
SM 224
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralDepartment Of State Health Services, Pharmacy Branch2009-04-07Not applicableUs
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralCentral Texas Community Health Centers2009-04-07Not applicableUs
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralNovartis2009-04-07Not applicableUs00078 0568 45 nlmimage10 6c443641
Categories
UNII
C7D6T3H22J
CAS number
71963-77-4
Weight
Average: 298.3746
Monoisotopic: 298.178023942
Chemical Formula
C16H26O5
InChI Key
SXYIRMFQILZOAM-HVNFFKDJSA-N
InChI
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecane
SMILES

Pharmacology

Indication

Artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.

Structured Indications
Pharmacodynamics

In the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.

Mechanism of action

Involves an interaction with ferriprotoporphyrin IX (“heme”), or ferrous ions, in the acidic parasite food vacuole, which results in the generation of cytotoxic radical species.

The generally accepted mechanism of action of peroxide antimalarials involves interaction of the peroxide-containing drug with heme, a hemoglobin degradation byproduct, derived from proteolysis of hemoglobin. This interaction is believed to result in the formation of a range of potentially toxic oxygen and carbon-centered radicals.

Absorption

Food increases absorption.

Volume of distribution
Not Available
Protein binding

Artemether and lumefantrine are both highly bound to human serum proteins in vitro (95.4% and 99.7%, respectively). Dihydroartemisinin is also bound to human serum proteins (47% to 76%).

Metabolism

Rapidly metablized to its active metabolite, dihydroartemisinin.

Route of elimination
Not Available
Half life

Artemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr

Clearance
Not Available
Toxicity

Animal studies on acute toxicity show that the LD50 of Artemether in mice is a single i.g. administration of 895mg/kg and a single i.m. injection of 296mg/kg dose; in rats, the LD50 is a single i.m. injection of 597mg/kg dose.

Affected organisms
  • Plasmodium
Pathways
PathwayCategory
Artemether Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Artemether.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when Artemether is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AbirateroneThe serum concentration of Artemether can be increased when it is combined with Abiraterone.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Artemether.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Artemether.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Artemether.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Artemether.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Artemether.Approved, Investigational
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Artemether.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Artemether.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Artemether.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Artemether.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Artemether.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Artemether.Approved, Withdrawn
AmiodaroneThe metabolism of Artemether can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Artemether.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Amlodipine.Approved
AmodiaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Artemether.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Artemether.Approved, Illicit
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Artemether.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Artemether is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Artemether.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Artemether.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Artemether.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AprepitantThe serum concentration of Artemether can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Artemether.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved, Investigational
ArmodafinilThe metabolism of Artemether can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Artemether.Approved, Investigational
ArtemisininThe risk or severity of adverse effects can be increased when Artemether is combined with Artemisinin.Investigational
ArtemotilThe risk or severity of adverse effects can be increased when Artemether is combined with Artemotil.Experimental
ArtenimolThe risk or severity of adverse effects can be increased when Artemether is combined with Artenimol.Approved, Investigational
ArtesunateThe risk or severity of adverse effects can be increased when Artemether is combined with Artesunate.Approved, Investigational
AsenapineThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Artemether.Approved, Withdrawn
AtazanavirThe metabolism of Artemether can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Artemether.Approved
AtovaquoneThe risk or severity of adverse effects can be increased when Artemether is combined with Atovaquone.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Artemether.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Artemether is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Artemether.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Artemether.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Artemether is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Benidipine.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Artemether.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Artemether.Approved
BepridilThe risk or severity of adverse effects can be increased when Artemether is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Artemether.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Artemether.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Artemether.Investigational
BoceprevirThe metabolism of Artemether can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
BosentanThe serum concentration of Artemether can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Artemether.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Artemether.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Artemether.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Artemether.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Artemether.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Artemether can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Artemether.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Artemether.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Artemether.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Artemether.Approved
CapecitabineThe metabolism of Artemether can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Artemether.Approved
CarbamazepineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Artemether is combined with Carboxyamidotriazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Artemether.Approved
CaroverineThe risk or severity of adverse effects can be increased when Artemether is combined with Caroverine.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Artemether.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Artemether.Approved, Investigational
CelecoxibThe metabolism of Artemether can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Artemether.Approved, Vet Approved
CeritinibThe serum concentration of Artemether can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Artemether.Approved
ChloramphenicolThe metabolism of Artemether can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Artemether.Approved, Illicit
ChloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Artemether.Investigational, Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Artemether.Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Artemether.Experimental
ChlorproguanilThe risk or severity of adverse effects can be increased when Artemether is combined with Chlorproguanil.Investigational
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Artemether.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.Approved
CholecalciferolThe metabolism of Artemether can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Artemether.Approved
CimetidineThe metabolism of Artemether can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Artemether can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Cinnarizine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Artemether.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Artemether can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Artemether can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Artemether can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Clevidipine.Approved
ClobazamThe metabolism of Artemether can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Artemether.Approved
ClopidogrelThe metabolism of Artemether can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Artemether can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Artemether can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Artemether can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Artemether can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.Approved, Illicit
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Artemether.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Artemether.Approved
CrisaboroleThe metabolism of Artemether can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Artemether can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
Cycloguanil embonateThe risk or severity of adverse effects can be increased when Artemether is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Artemether.Approved
DapsoneThe risk or severity of adverse effects can be increased when Artemether is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Artemether can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Darodipine.Experimental
DarunavirThe serum concentration of Artemether can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Artemether.Approved
DasatinibThe serum concentration of Artemether can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Artemether.Approved, Investigational
DeferasiroxThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Artemether.Approved
DelavirdineThe metabolism of Artemether can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Artemether.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Artemether.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Artemether.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Artemether.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Artemether.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Artemether.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Artemether.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Artemether.Approved
DidanosineDidanosine can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Artemether.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Artemether.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Artemether.Approved, Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.Approved, Illicit
DihydroergotamineThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Artemether is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Artemether.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Artemether.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Artemether.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Artemether.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Artemether.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Artemether.Approved
DosulepinThe metabolism of Artemether can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Dotarizine.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Artemether.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Artemether.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Artemether.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Artemether.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Artemether is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Artemether can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Artemether.Approved
DuloxetineThe metabolism of Artemether can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Artemether.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Artemether.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Artemether.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Artemether.Investigational
EnzalutamideThe serum concentration of Artemether can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Artemether is combined with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Artemether.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Artemether.Approved, Investigational
ErythromycinThe metabolism of Artemether can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Artemether.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Artemether can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Artemether.Investigational
EsomeprazoleThe metabolism of Artemether can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Artemether.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Artemether.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Artemether.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Artemether.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Artemether.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Artemether.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Artemether.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Artemether.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Artemether.Approved
FelodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Artemether is combined with Fendiline.Withdrawn
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Artemether.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Artemether.Approved, Withdrawn
FloxuridineThe metabolism of Artemether can be decreased when combined with Floxuridine.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Artemether.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Flunarizine.Approved
FluorouracilThe metabolism of Artemether can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Artemether can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Artemether.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Artemether.Approved
FluvoxamineThe metabolism of Artemether can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FosamprenavirThe metabolism of Artemether can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Artemether can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Artemether.Approved
FosphenytoinThe serum concentration of Artemether can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Artemether can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Artemether is combined with Gabapentin.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Artemether.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Artemether.Approved
GallopamilThe risk or severity of adverse effects can be increased when Artemether is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Artemether.Approved, Investigational
GemfibrozilThe metabolism of Artemether can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Artemether.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Artemether.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Artemether.Approved, Investigational
HalofantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Halofantrine.Approved
HaloperidolThe metabolism of Artemether can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Artemether.Approved, Vet Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Artemether.Withdrawn
HistrelinHistrelin may increase the QTc-prolonging activities of Artemether.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Artemether.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Artemether.Approved, Illicit
HydroxychloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Artemether.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Artemether.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Artemether.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Artemether.Approved
IdelalisibThe serum concentration of Artemether can be increased when it is combined with Idelalisib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Artemether.Approved
ImatinibThe metabolism of Artemether can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Artemether.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Artemether.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Artemether.Approved
IndinavirThe metabolism of Artemether can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.Approved
IrbesartanThe metabolism of Artemether can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Artemether can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
IsoniazidThe metabolism of Artemether can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Artemether.Approved
ItraconazoleThe metabolism of Artemether can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Artemether.Approved
IvacaftorThe serum concentration of Artemether can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Artemether.Approved
KetoconazoleThe metabolism of Artemether can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Artemether.Approved
LacidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Artemether is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LeflunomideThe metabolism of Artemether can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Artemether.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lercanidipine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Artemether.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Artemether.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Artemether.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Artemether.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Artemether.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Artemether is combined with Lidoflazine.Experimental
LisurideThe metabolism of Lisuride can be decreased when combined with Artemether.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Artemether.Approved
LobeglitazoneThe metabolism of Artemether can be decreased when combined with Lobeglitazone.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Artemether.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Artemether.Approved
LopinavirThe metabolism of Artemether can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Artemether.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Artemether.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Artemether.Approved
LovastatinThe metabolism of Artemether can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Artemether can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Artemether can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Lumefantrine.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Artemether.Investigational
Magnesium SulfateThe risk or severity of adverse effects can be increased when Artemether is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Artemether.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Artemether is combined with Mefloquine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Artemether.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Artemether.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Artemether.Approved
MethadoneThe metabolism of Artemether can be decreased when combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Artemether.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Artemether.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Artemether.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Artemether.Approved, Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Artemether.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Artemether.Approved, Illicit, Withdrawn
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Artemether.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Artemether.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Artemether.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Artemether.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Artemether is combined with Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Artemether can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Artemether can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Artemether.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Artemether.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Artemether.Approved
MitotaneThe serum concentration of Artemether can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Artemether is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Artemether.Approved
ModafinilThe metabolism of Artemether can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Artemether.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Artemether.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Artemether.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Artemether is combined with Naftopidil.Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Artemether.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved, Investigational
NefazodoneThe metabolism of Artemether can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Artemether can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Artemether can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Artemether can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Artemether.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Artemether.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Artemether.Approved
NifedipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niguldipine.Experimental
NilotinibThe metabolism of Artemether can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Artemether.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Artemether.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Artemether.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Artemether.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Artemether.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Artemether.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OlaparibThe metabolism of Artemether can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Artemether.Approved
OmeprazoleThe metabolism of Artemether can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Artemether.Approved
OsimertinibThe serum concentration of Artemether can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Artemether is combined with Otilonium.Experimental, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Artemether.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
PalbociclibThe serum concentration of Artemether can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Artemether.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Artemether.Approved, Investigational
PanobinostatThe serum concentration of Artemether can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Artemether can be decreased when combined with Pantoprazole.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Artemether.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Artemether.Approved
Peginterferon alfa-2bThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Artemether.Approved
PentobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Artemether.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Artemether.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Artemether is combined with Perhexiline.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Artemether.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Artemether.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Artemether.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Artemether.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Artemether.Approved, Vet Approved
PimozideArtemether may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Artemether is combined with Pinaverium.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Artemether.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Artemether.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Artemether.Approved, Investigational
PonatinibThe metabolism of Ponatinib can be decreased when combined with Artemether.Approved
PosaconazoleThe metabolism of Artemether can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Artemether is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Artemether is combined with Prenylamine.Withdrawn
PrimaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Primaquine.Approved
PrimidoneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Primidone resulting in a loss in efficacy.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Artemether.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.Approved, Vet Approved
ProguanilThe risk or severity of adverse effects can be increased when Artemether is combined with Proguanil.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Artemether.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Artemether.Approved
PropafenoneThe serum concentration of Artemether can be increased when it is combined with Propafenone.Approved
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Artemether.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Artemether.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Artemether.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Artemether.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Artemether.Approved
PyrimethamineThe risk or severity of adverse effects can be increased when Artemether is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe risk or severity of adverse effects can be increased when Artemether is combined with Pyronaridine.Investigational
QuazepamThe serum concentration of Artemether can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Artemether.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinacrine.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Artemether.Approved
QuinineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Artemether is combined with Radicicol.Experimental
RanitidineThe metabolism of Ranitidine can be decreased when combined with Artemether.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Artemether.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Artemether.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Artemether.Investigational
RifabutinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifabutin resulting in a loss in efficacy.Approved
RifampicinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifapentineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifapentine resulting in a loss in efficacy.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Artemether.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Artemether.Approved
RisedronateThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Artemether.Approved, Investigational
RolapitantThe metabolism of Artemether can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Artemether can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Artemether.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Artemether.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Artemether.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Artemether.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Artemether.Approved
SaquinavirThe metabolism of Artemether can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Artemether.Approved
SecobarbitalThe metabolism of Artemether can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Artemether.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SildenafilThe metabolism of Artemether can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Artemether can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Artemether can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Artemether.Approved
SinefunginThe risk or severity of adverse effects can be increased when Artemether is combined with Sinefungin.Experimental
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Artemether.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Artemether.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Artemether.Experimental
St. John's WortThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.Investigational, Nutraceutical
StiripentolThe serum concentration of Artemether can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe metabolism of Artemether can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Artemether.Approved
SulfametopyrazineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleThe metabolism of Artemether can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Artemether.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Artemether.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Artemether.Approved, Investigational
tafenoquineThe risk or severity of adverse effects can be increased when Artemether is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Artemether.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Artemether.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Artemether.Investigational, Withdrawn
TelaprevirThe metabolism of Artemether can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Artemether.Approved
TelithromycinThe metabolism of Artemether can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Artemether can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Artemether.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Artemether.Withdrawn
TerodilineThe risk or severity of adverse effects can be increased when Artemether is combined with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Artemether.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Artemether.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Artemether is combined with Tetrahydropalmatine.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Artemether.Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Artemether.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Artemether.Withdrawn
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Artemether.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Artemether.Approved, Withdrawn
ThiotepaThe metabolism of Artemether can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Artemether.Approved
TicagrelorThe metabolism of Artemether can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Artemether can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Artemether.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Artemether.Approved
TipranavirThe metabolism of Artemether can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Artemether.Approved
TocilizumabThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Artemether can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Artemether is combined with Tolfenamic Acid.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TopiramateThe metabolism of Artemether can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Artemether can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Artemether.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Artemether.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Artemether can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.Approved, Vet Approved
TrimethoprimThe risk or severity of adverse effects can be increased when Artemether is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Artemether.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Artemether.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Artemether.Approved, Investigational
Valproic AcidThe metabolism of Artemether can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Artemether can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Vandetanib is combined with Artemether.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Artemether.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Artemether is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Artemether.Approved
VerapamilThe risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Artemether.Approved, Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Artemether.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Artemether.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Artemether.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Artemether.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Artemether is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Artemether can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Artemether.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Artemether.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Artemether.Approved, Vet Approved
ZafirlukastThe metabolism of Artemether can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Artemether.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Artemether is combined with Ziconotide.Approved
ZiprasidoneThe metabolism of Artemether can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Artemether.Approved
ZucapsaicinThe metabolism of Artemether can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Artemether.Approved, Investigational
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of artemether and lumefantrine.

References

Synthesis Reference

Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. Pubmed.

General References
  1. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5. [PubMed:19818172]
  2. Mutabingwa TK, Adam I: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169. [PubMed:23409819]
  3. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. [PubMed:8053018]
External Links
Human Metabolome Database
HMDB15643
KEGG Drug
D02483
PubChem Compound
68911
PubChem Substance
99443251
ChemSpider
62138
BindingDB
50022886
ChEBI
195280
ChEMBL
CHEMBL566534
PharmGKB
PA165111698
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Artemether
ATC Codes
P01BE02 — ArtemetherP01BF01 — Artemether and lumefantrine
FDA label
Download (1.73 MB)
MSDS
Download (566 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionPlasmodium Infections1
1CompletedNot AvailableHealthy Volunteers / Plasmodium Infections1
1CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentMalaria caused by Plasmodium falciparum1
1CompletedTreatmentMalaria caused by plasmodium vivax1
1, 2RecruitingTreatmentTumors, Solid1
2Active Not RecruitingTreatmentPlasmodium Infections1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2Not Yet RecruitingTreatmentPlasmodium Infections1
2RecruitingTreatmentAcute Uncomplicated Plasmodium Falciparum Malaria1
3Active Not RecruitingTreatmentPlasmodium Falciparum Infection1
3CompletedTreatmentMalaria caused by plasmodium vivax1
3CompletedTreatmentMalaria in Pregnancy1
3CompletedTreatmentPlasmodium Falciparum Malaria2
3CompletedTreatmentPlasmodium Infections10
3RecruitingTreatmentPlasmodium Infections1
3Unknown StatusTreatmentPlasmodium Infections1
4CompletedNot AvailablePlasmodium Infections1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
4CompletedBasic SciencePlasmodium Falciparum Clinical Episode / Plasmodium Falciparum Infection / Plasmodium Vivax Clinical Episode / Plasmodium Vivax Infection1
4CompletedHealth Services ResearchAnemias / Plasmodium Infections / Pregnancy1
4CompletedTreatmentFalciparum / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Plasmodium Infections1
4CompletedTreatmentInstantaneous Clearance1
4CompletedTreatmentMalaria caused by Plasmodium falciparum4
4CompletedTreatmentParasitologically Confirmed; Malarial1
4CompletedTreatmentPlasmodium Falciparum Malaria1
4CompletedTreatmentPlasmodium Infections8
4RecruitingNot AvailablePlasmodium Infections1
4RecruitingTreatmentPlasmodium Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4TerminatedTreatmentMalaria caused by Plasmodium falciparum1
4TerminatedTreatmentPlasmodium Infections1
4TerminatedTreatmentPlasmodium Vivax Malaria1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4Unknown StatusTreatmentPlasmodium Infections2
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
4Unknown StatusTreatmentUncomplicated Malaria1
Not AvailableCompletedHealth Services ResearchPlasmodium Infections / Pneumonia1
Not AvailableCompletedOtherPlasmodium Infections1
Not AvailableCompletedTreatmentMalaria caused by Plasmodium falciparum1
Not AvailableCompletedTreatmentNon-malarial Febrile Illness / Plasmodium Infections1
Not AvailableCompletedTreatmentPlasmodium Infections2
Not AvailableCompletedTreatmentPlasmodium Infections / Pneumonia1
Not AvailableCompletedTreatmentUncomplicated Malaria2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)86-90Not Available
water solubilityInsoluble # http://www.rxlist.com/coartem-drug.htm
logP3.53AVERY,MA ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP3.02ALOGPS
logP3.48ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability32.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9012
Blood Brain Barrier+0.9393
Caco-2 permeable+0.7876
P-glycoprotein substrateSubstrate0.6031
P-glycoprotein inhibitor IInhibitor0.8918
P-glycoprotein inhibitor IINon-inhibitor0.7056
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8665
CYP450 2D6 substrateSubstrate0.5341
CYP450 3A4 substrateSubstrate0.7023
CYP450 1A2 substrateInhibitor0.6829
CYP450 2C9 inhibitorNon-inhibitor0.9413
CYP450 2D6 inhibitorNon-inhibitor0.9474
CYP450 2C19 inhibitorNon-inhibitor0.8733
CYP450 3A4 inhibitorNon-inhibitor0.9434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9672
Ames testNon AMES toxic0.7285
CarcinogenicityNon-carcinogens0.9179
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.2114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.86 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0950000000-2ae4d4c9200a42ec883d

Taxonomy

Description
This compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Sesquiterpenoids
Direct Parent
Artemisinins
Alternative Parents
Oxepanes / Trioxanes / Oxanes / Dialkyl peroxides / Oxacyclic compounds / Acetals / Hydrocarbon derivatives
Substituents
Artemisinin skeleton / Oxepane / 1,2,4-trioxane / Oxane / Dialkyl peroxide / Oxacycle / Organoheterocyclic compound / Acetal / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
semisynthetic derivative, sesquiterpenoid, artemisinin derivative, cyclic acetal, organic peroxide (CHEBI:195280)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on May 05, 2010 12:03 / Updated on November 09, 2017 03:54